1 / 6

Comparison of PI vs PI

Comparison of PI vs PI. ATV vs ATV/r BMS 089 LPV/r mono vs LPV/r + ZDV/3TC MONARK LPV/r QD vs BID M02-418 M05-730 A5073 LPV/r + 3TC vs LPV/r + 2 NRTI GARDEL ATV/r vs FPV/r ALERT ATV/r vs DRV/r ATADAR FPV/r vs LPV/r KLEAN SQV/r vs LPV/r GEMINI ATV/r vs LPV/r CASTLE

hbess
Download Presentation

Comparison of PI vs PI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Comparison of PI vs PI • ATV vs ATV/r BMS 089 • LPV/r mono vs LPV/r + ZDV/3TC MONARK • LPV/r QD vs BIDM02-418M05-730A5073 • LPV/r + 3TC vs LPV/r + 2 NRTI GARDEL • ATV/r vs FPV/r ALERT • ATV/r vs DRV/r ATADAR • FPV/r vs LPV/r KLEAN • SQV/r vs LPV/rGEMINI • ATV/r vs LPV/r CASTLE • DRV/r vs LPV/r ARTEMIS

  2. GEMINI Study: SQV/r BID vs LPV/r BID,in combination with TDF/FTC GEMINI • Design Randomisation* 1 : 1 Open-label W48 > 18 years ARV-naïve or < 2 weeks of prior ARV exposure HIV RNA > 10,000 c/mL CD4 < 350/mm3 No active HBV infection N = 167 N = 170 SQV was administered as 500 mg tablet; LPV/r as soft-gel capsule, changed to tablet when it became available • Objective • Non inferiority of SQV/r vs LPV/r at W48: % HIV RNA < 50 c/mL,ITT-Exposed, Missing = Failure (lower margin of the 1-sided 98% [equivalent to 2-sided 96%] CI for the difference = - 12%) Walmsley S. JAIDS 2009;50:367-74

  3. GEMINI Study: SQV/r BID vs LPV/r BID,in combination with TDF/FTC GEMINI Baseline characteristics and patient disposition Walmsley S. JAIDS 2009;50:367-74

  4. GEMINI Study: SQV/r BID vs LPV/r BID,in combination with TDF/FTC GEMINI Response to treatment at week 48 % HIV RNA < 50 c/mL Median CD4 (/mm3) increase 100 Primary efficacy endpoint 204 SQV/r 200 178 80 LPV/r 65.5 64.7 63.5 62.1 160 60 120 40 80 20 40 N = 167 170 148 145 0 ITT-E,M = F Per protocol 0 96% CI for the difference= - 9.6; 11.9 96% CI for the difference= - 8.1; 15.0 p = 0.33 Virologic failures (2 consecutive HIV RNA > 400 c/mL at W16 or after): 11 (7%) (SQV/r) vs 5 (3%) (LPV/r) Emergence of M184V: 5/11 SQV/r vs 4/5 LPV/r; emergence of major PI mutations: 1 SQV/r vs 0 LPV/r ITT-E, M = F: ITT-exposed, missing = failure Walmsley S. JAIDS 2009;50:367-74

  5. GEMINI Study: SQV/r BID vs LPV/r BID,in combination with TDF/FTC Safety and tolerability: SQV/r vs LPV/r Low frequency of premature discontinuations for adverse events:3% vs 7% Most frequent reported adverse events of any grade were gastrointestinal disorders: 17% vs 27% No discontinuation because of renal-related adverse events; 2 patients, in the LPV/r arm, had elevated plasma creatinine levels > 2 mg/dL attributed to TDF/FTC Median changes at W48 in total, LDL- and HDL-cholesterol were not significantly different between treatment groups; elevation of triglycerides was significantly higher in the LPV/r arm GEMINI Walmsley S. JAIDS 2009;50:367-74

  6. GEMINI Study: SQV/r BID vs LPV/r BID,in combination with TDF/FTC Conclusions SQV/r BID was non inferior to LPV/r BID, in combination withTDF/FTC fdc Virologic and immunologic responses were similar in both arms Tolerability was similar in both arms Gastrointestinal adverse events were more frequent with LPV/r Lipid changes were not different between SQV/r and LPV/r except for triglycerides elevation, which was higher with LPV/r Rate of virologic failure was low in both groups 1 patient in the SQV/r group developed new major protease resistance mutations at virologic failure GEMINI Walmsley S. JAIDS 2009;50:367-74

More Related